AB004. OS01.04. Prevalence of autoimmune diseases in thymic epithelial tumors insights from RYTHMIC

Marie-Eve Boucher¹, Eric Dansin², Mallorie Kerjouan³, Julien Mazieres⁴, Eric Pichon⁵, François Thillays⁶, Gilbert Massard⁷, Xavier Quantin⁸, Youssef Oulkhouir⁹, Virginie Westeel¹⁰, Luc Thiberville¹¹, Christelle Clement-Duchene¹², Franck Morin¹³, Pascal Thomas¹⁴, Nicolas Girard¹⁵, Benjamin Besse¹

¹Medical Oncology Department, Gustave Roussy, Villejuif, France; ²Thoracic Oncology Department, Oscar Lambret, Lille, France; ³Department of Pulmonology, Centre Hospitalier Universitaire de Rennes, Rennes, France; ⁴Department of Pulmonology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; ⁵Department of Pulmonology, Hôpital Bretonneau, Tours, France; ⁶Radiation Oncology Department, Institut de Cancérologie de l’ouest, Rouen, France; ⁷Thoracic Surgery Department, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France; ⁸Department of Pulmonology and Addictology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; ⁹Department of Pulmonology, Centre Hospitalier Universitaire de Caen, Caen, France; ¹⁰Department of Pulmonology, Centre Hospitalier Universitaire de Besançon, Besançon, France; ¹¹Department of Pulmonology, Centre Hospitalier Universitaire de Rouen, Rouen, France; ¹²Medical Oncology Department, Institut de Cancérologie de Lorraine, Nancy, France; ¹³Clinical Research Department, Intergroupe francophone de cancérologie thoracique, Paris, France; ¹⁴Thoracic Surgery Department, Hôpital Nord, Marseille, France; ¹⁵Medical Oncology Department, Université Lyon 1, Institut Curie, Paris, France

Background: Thymic epithelial tumor (TET) has been associated with autoimmune disorders (AID) in up to 30% of patients. However, there have been wide variations in the reported prevalence of TET associated disorders based mostly on small single center series. RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French network mandated to systematically discuss every case of TET. Using our database, we aimed to describe the prevalence of AID in a large French TET population.

Methods: RYTHMIC database prospectively includes all consecutive patients with a diagnosis of TET discussed in our national tumor board. We calculated the prevalence and described epidemiologic, clinical and pathological characteristics of patients with TET’s related autoimmune diseases.

Results: From January 2012 to May 2017, 1,581 patients were included in the registry. Of these, 312 patients (19.7%) had autoimmune disorder. The mean age at diagnosis of TET was 56 years old and 52% were female. 233 had myasthenia gravis (65.8%), 19 Good syndrome (5.4%), 17 thyroiditis (4.8%), 16 systemic erythematous lupus (4.5%) and 14 pure red cell aplasia (4%). Some patients (10.3 %) eventually developed more than 1 AID. Considering histologic characterization, 42.9% were B2 subtype, 17.1% AB subtype, 16.1% B3 subtype, 12.1% B1 subtype, 3.6 % thymic carcinoma and 3.6% A subtype.

Conclusions: In our database of TET, the prevalence of autoimmune diseases was 11.8%, mostly in patients with B2, AB and B3 subtypes. This significant prevalence means that physicians must keep high awareness and systematically search for those comorbidities.

Keywords: Autoimmune diseases; thymoma

doi: 10.21037/med.2017.AB004